SUMMARY The metabolism of endogenous arachidonic acid P(AA) was investigated in activated neutrophils from 20 patients with Crohn's disease, 20 with ulcerative colitis, and 25 healthy volunteers. 1-'4C-P(AA) was incorporated into intracellular pools of phospholipids prior to activation of the cells with ionophore A23187 and analyses of released arachidonic acid metabolites by thin layer chromatography. Total release of radioactivity expressing the release of arachidonic acid and its metabolites, was equal in the experimental and control groups, which suggests a normal substrate availability. In contrast, there was a marked increase in the relative release of leucotriene B4 (LTB4) and its 0-oxidation products, 20-hydroxy-LTB4 (20-OH-LTB4) and 20-carboxy-LTB4 (20-COOH-LTB4), with LTB4 values exceeding the reference interval in seven of 20 patients with Crohn's disease, median 8.7%, and in six of 20 patients with ulcerative colitis, median 7.7%, as compared with a median of 5.3% in healthy volunteers. Furthermore, a decreased release of unmetabolised arachidonic acid, correlating inversely with the release of LTB4 in all experimental and control groups, and normal values for the production of other metabolites of arachidonic acidfor example, 5-hydroxyeicosatetraenoic acid (5-HETE) and 12-hydroxyheptadecatrienoic acid (HHT), point to an enzymatic abnormality such as increased activity of leucotriene B synthetase. An increased capacity for release of LTB4, the major pro-inflammatory metabolite of arachidonic acid lipoxygenation by polymorphonuclear leucocytes, may contribute to perpetuation of the inflammation and to tissue destruction in chronic inflammatory bowel disease. Our findings agree with previous reports of an increased release of LTB4 by the colonic mucosa in this condition. 
Polymorphonuclear leucocytes possibly play a role in the pathogenesis of chronic inflammatory bowel disease. Involvement of complement'`3 with resulting release of the chemotactic split product C5a' thus may account for their vast numbers in the colonic exudate of patients with ulcerative colitis.56 Local accumulation and activation of this cellular element of inflammation with release of toxic oxygen metabolites, lysosomal enzymes, and metabolites of arachidonic acid, such as leucotriene B4 (LTB4), the less potent w-oxidation products, 20-OH-LTB4 and 20-COOH-LTB4, and 5-hydroxyeicosatetraenoic acid (5-HETE) accordingly may contribute to perpetuation of inflammation and tissue destruction in chronic inflammatory bowel disease as it does in rheumatoid arthritis. ' Biopsy specimens of affected colonic mucosa from patients with chronic inflammatory bowel disease show increased production of the lipoxygenase products of arachidonic acid, and increased release of prostaglandins and leucotnenes has been shown in vitro, '9 and in vivo in patients with ulcerative colitis."' " The cell type and stimulus responsible for this production of inflammatory mediators have not yet been identified.
A recent study showed a marked abnormality in the oxidative metabolism of polymorphonuclear leucocytes in Crohn's disease as assessed by the release of hydrogen peroxide (H202) and superoxide 
Results
Total radioactivity released, representing arachidonic acid and its metabolites, was equal in patients and control groups ( Table 2) .
The relative distribution of arachidonic acid and biologically active metabolites was abnormal in the patients. The 5-lipoxygenase product, LTB4, was increased in seven of 20 patients with Crohn's disease colitis (p<001) as compared with the healthy volunteers ( Fig. 1 and Table 3 ). Furthermore, the two woxidation products, 20-OH-LTB4 and 20-COOH-LTB4, which were not resolved in the TLC-system I, were raised in parallel with LTB4 (Table 3 ). In additional experiments using TLC-system II, which separates 20-OH-LTB4 and 20-COOH-LTB4, the ratio between these two compounds was found to be median 3-4:1 (1.9-5-5, n= 10). In contrast, the values for the less potent lipoxygenase metabolite, 5-HETE, and for the cyclo-oxygenase metabolite,
HHT, did not differ between patients and controls (Table 3) indicating an increased total capacity for metabolising endogenously released arachidonic acid (Fig. 2 ). An inverse correlation between released M4C-AA and '4C-LTB4 expressed in per cent of total released radioactivity could be established in each of the three groups, ulcerative colitis patients (r=-0 815; p<0.01), Crohn's disease patients (r=-0-875; p<0-01), and healthy volunteers (r=-0.806; p<O-Ol).
The specific activity of LTB4 was equal in the two groups tested, 4-1 x 108 Bq/mmol (range 2-9-5.5) and 5-4x 10' Bq/mmol (range 3-4-6-9) in patients with Crohn's disease and in healthy volunteers, respectively.
None of the data correlated with clinical scores of disease activity, with duration of the disease, or with the site of intestinal involvement.
Discussion
Arachidonic acid is metabolised by oxygenation through separate pathways`of which the 5-lipoxygenase pathway leading to the inflammatory mediators LTB4 and 5-HETE seems to be the major route in human polymorphonuclear leucocytes.`0 Increased release of these metabolites by the colonic mucosa in ulcerative colitis09 1120 may reflect release from inflammatory polymorphonuclear leucocytes, at least as judging by animal experiments.2 Our data suggest an underlying enzymatic defect of the circulating neutrophil. As the enzyme responsible for leucotriene synthesis, 5-lipoxygenase, has been shown to exhibit an absolute requirement for calcium ions,22 we have chosen to study the stimulation induced by calcium ionophore A23187. Although this is an unphysiologic agent it is assumed to produce the maximal synthesis of leucotrienes in response to calcium influx. The procedure therefore reflects the total capacity for leucotriene synthesis in human polymorphonuclear leucocytes. Activated polymorphonuclear leucocytes revealed an increased capacity for metabolising endogenously released arachidonic acid into LTB4 and the less potent woxidation products - More information about the complex way in which arachidonic acid is metabolised in the diseased and normal intestine may provide a base for further rational approaches in the treatment of chronic inflammatory bowel disease. 
